title: Responding to an FDA warning--geographic variation in the use of rosiglitazone.
authors.affiliation: Knowledge and Encounter Research Unit, Mayo Clinic, Rochester, MN, USA.
authors.forename: Nilay D
authors.initials: ND
authors.lastname: Shah
authors.forename: Victor M
authors.initials: VM
authors.lastname: Montori
authors.forename: Harlan M
authors.initials: HM
authors.lastname: Krumholz
authors.forename: Karen
authors.initials: K
authors.lastname: Tu
authors.forename: G Caleb
authors.initials: GC
authors.lastname: Alexander
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Jackevicius
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D004363:Drug Utilization / Q000706:statistics & numerical data; D005843:Geography; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone